Last reviewed · How we verify
Placebo to Atorvastatin
Placebo to Atorvastatin is a HMG-CoA reductase inhibitor (statin) Small molecule drug developed by Amgen. It is currently in Phase 3 development for Hypercholesterolemia and cardiovascular risk reduction (specific indication dependent on Phase 3 trial design).
This is a Phase 3 trial comparing placebo to atorvastatin, a statin that lowers cholesterol by inhibiting HMG-CoA reductase.
This is a Phase 3 trial comparing placebo to atorvastatin, a statin that lowers cholesterol by inhibiting HMG-CoA reductase. Used for Hypercholesterolemia and cardiovascular risk reduction (specific indication dependent on Phase 3 trial design).
At a glance
| Generic name | Placebo to Atorvastatin |
|---|---|
| Sponsor | Amgen |
| Drug class | HMG-CoA reductase inhibitor (statin) |
| Target | HMG-CoA reductase |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular |
| Phase | Phase 3 |
Mechanism of action
Atorvastatin is an established HMG-CoA reductase inhibitor that reduces LDL cholesterol synthesis in the liver, leading to decreased circulating LDL levels and reduced cardiovascular risk. The Phase 3 trial is evaluating atorvastatin's efficacy and safety in a specific patient population compared to placebo control.
Approved indications
- Hypercholesterolemia and cardiovascular risk reduction (specific indication dependent on Phase 3 trial design)
Common side effects
- Muscle pain or myalgia
- Elevated liver enzymes
- Headache
- Nausea
- Rhabdomyolysis
Key clinical trials
- Metformin Alleviates Abnormal Glucose Metabolism Induced by Statins in Schizophrenia Patients (PHASE3)
- Atorvastatin for Preventing Disease Metastasis in Patients With Resected High-Risk Stage IIA, IIB, or IIIA Melanoma (PHASE2)
- Statins Against Bushfire Smoke (PHASE4)
- Atorvastatin to Reduce Cisplatin-Induced Hearing Loss Among Individuals With Head and Neck Cancer (PHASE2)
- Atorvastatin Pretreatment in Cerebrovascular Events (APICES) After Flow Diverter Implantation (PHASE4)
- Combined Effects of Statins and Exercise on Training Sensitive Health Markers (NA)
- Vascular Endothelial Dysfunction in Sleep Apnea (PHASE1)
- Polypill and Colchicine for Risk Reduction in Atherosclerotic Cardiovascular Disease (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Placebo to Atorvastatin CI brief — competitive landscape report
- Placebo to Atorvastatin updates RSS · CI watch RSS
- Amgen portfolio CI
Frequently asked questions about Placebo to Atorvastatin
What is Placebo to Atorvastatin?
How does Placebo to Atorvastatin work?
What is Placebo to Atorvastatin used for?
Who makes Placebo to Atorvastatin?
What drug class is Placebo to Atorvastatin in?
What development phase is Placebo to Atorvastatin in?
What are the side effects of Placebo to Atorvastatin?
What does Placebo to Atorvastatin target?
Related
- Drug class: All HMG-CoA reductase inhibitor (statin) drugs
- Target: All drugs targeting HMG-CoA reductase
- Manufacturer: Amgen — full pipeline
- Therapeutic area: All drugs in Cardiovascular
- Indication: Drugs for Hypercholesterolemia and cardiovascular risk reduction (specific indication dependent on Phase 3 trial design)
- Compare: Placebo to Atorvastatin vs similar drugs
- Pricing: Placebo to Atorvastatin cost, discount & access